John E Levine, MD
- PROFESSOR | Medicine, Hematology and Medical Oncology
- PROFESSOR | Pediatrics
- Cancer (Oncology)
- Pediatric Hematology-Oncology
- Hospital Affiliation
- The Mount Sinai Hospital
- Ruttenberg Treatment Center 212-241-6021 212-241-6021
My clinical practice focuses exclusively on patients (both adult and pediatric) who undergo Bone Marrow Transplant (BMT) and overlaps with my clinical research. I have designed, conducted, analyzed, and authored multiple clinical trials and data analyses of clinical GVHD, specifically, and clinical BMT, broadly. My long term goal is to improve outcomes for patients who undergo BMT by designing and conducting high impact clinical trials.
I co-direct the Mount Sinai Acute GVHD International Consortium [MAGIC] with James Ferrara, MD. This international consortium provides the opportunity to develop and test innovative treatment approaches for allogeneic BMT patients.
Pediatric Hematology & Oncology
- Acute Lymphoid Leukemia
- Acute Myeloid Leukemia
- Adult Non-Hodgkin's Lymphoma
- Bone Marrow Transplantation
- Hematologic Malignancies
- Hematologic Malignancies, Pediatric
MD, Eastern Virginia Medical School
Childrens Hospital of Los Angeles
Fellowship, Pediatric Hematology/Oncology
Memorial Sloan-Kettering Cancer Center
Chair, Pediatric Scientific Interest Group, ASBMT Annual Meeting
Chair, Scientific Program, ASBMT Annual Meeting
Best Doctors in America
Ford Motor Company Leadership in Health Award
Immunosuppression, T Cells, Transplantation
My research focuses on clinical bone marrow transplantation. My primary research focus concentrates on clinical and translational studies for the diagnosis, prevention, and treatment of acute graft-versus-host disease (GVHD). In collaboration with the laboratory of James Ferrara, we developed and validated a GVHD plasma biomarker based scoring system that assigns patients to GVHD risk strata and can be used to determine treatment intensity.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Levine during 2020 and/or 2021. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
- Brennan Burtker
- Ironwood Pharmaceuticals
- Jazz Pharmaceuticals
- Mesoblast Ltd.
- The Piorkowski Law Firm
- X4 Pharmaceuticals
Other activities: Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership
- Bluebird Bio
Scientific Advisory Board:
- Incyte Corporation
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.